Inhibitex
Alpharetta
About Inhibitex
Inhibitex develops antibody based products to prevent and treat bacterial and fungal infections. The company is focused on the development of small molecule antiviral compounds, and in particular, therapies to treat shingles and chronic hepatitis C infections.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $121.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2009)
- Ticker: nasdaq:INHX
- Website: inhibitex.com
- Phone: +1 678 746 1100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inhibitex-1746713 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.